Empagliflozin for CKD trial launches

Boehringer Ingelheim and Eli Lilly announced plans to conduct a trial of empagliflozin, an SGLT2 inhibitor, for the treatment of chronic kidney disease in adults with and without type 2 diabetes, according to a company press release.

In the EMPA-REG Outcome trial, empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) was associated with a reduction in cardiovascular death and also reduced the risk for new-onset or worsening of kidney disease by 39% in adults with type 2 diabetes and cardiovascular disease. In December, the FDA approved an indication to reduce the risk for cardiovascular death

“Based on the [CV] and renal results of the EMPA-REG Outcome trial, we, along with Boehringer Ingelheim, look forward to starting this new trial to gather evidence in support of a potential new indication for empagliflozin in people with [CKD],” said Jeff Emmick, MD, PhD, vice president of product development at Lilly Diabetes, said in the release.

Boehringer Ingelheim and Eli Lilly announced plans to conduct a trial of empagliflozin, an SGLT2 inhibitor, for the treatment of chronic kidney disease in adults with and without type 2 diabetes, according to a company press release.

In the EMPA-REG Outcome trial, empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) was associated with a reduction in cardiovascular death and also reduced the risk for new-onset or worsening of kidney disease by 39% in adults with type 2 diabetes and cardiovascular disease. In December, the FDA approved an indication to reduce the risk for cardiovascular death

“Based on the [CV] and renal results of the EMPA-REG Outcome trial, we, along with Boehringer Ingelheim, look forward to starting this new trial to gather evidence in support of a potential new indication for empagliflozin in people with [CKD],” said Jeff Emmick, MD, PhD, vice president of product development at Lilly Diabetes, said in the release.